Skip to main content
. Author manuscript; available in PMC: 2014 Dec 12.
Published in final edited form as: Nature. 2014 Apr 23;510(7504):278–282. doi: 10.1038/nature13229

Extended Data Figure 9. JQ1 does not affect normal prostate growth and testosterone levels but reduces testis size in mice.

Extended Data Figure 9

a, Comparison of JQ1 and MDV3100 treatment on VCaP cell viability in vitro. N=8 wells of a 96 well plate per condition. VCaP cells were treated with MDV3100 or JQ1 for 8 days and assayed for viability with Cell-titerGLO. b, Gross images showing highly hormone-responsive seminal vesicles (s.v.) attached to prostate gland (red and black arrows respectively) from male mice treated for 30 days with vehicle, JQ1 (50mg/kg) or MDV3100 (10mg/kg). Vehicle or JQ1-treated mice show no change in the appearance of seminal vesicles. By contrast, MDV3100-treated animals display remarkable shrinkage of seminal vesicles. c, Mice treated with JQ1 do not show any adverse changes to anterior or ventral prostate morphology. The H&E images show normal morphology of anterior and ventral prostate from vehicle or JQ1-treated mice. MDV3100-treated mice display attenuated remnant glands of anterior or ventral prostate. d, Male mice (n =3 per group) treated with vehicle or JQ1 for 30 days exhibit similar serum testosterone levels. Data represents the mean ± S.E. e, Gross analysis of testis from mice treated with vehicle or JQ1 for 30 days. f, Testis weight from vehicle control or JQ1-treated mice. Data represents the mean ± S.E. from n=7 mice per group. NS, not significant; *P ≤ 0.0001 by two-tailed Student's t-test.